Literature DB >> 16125436

Fluorophore-tagged GPCR ligands.

Richard J Middleton1, Barrie Kellam.   

Abstract

Fluorescently tagged drug molecules can be successfully employed to visualize the location of their receptor target at the single-cell level. Furthermore, if their binding to the receptor is reversible, one can now obtain detailed pharmacological information such as affinity using single-molecule detection techniques. When coupled to the growing exploitation of fluorescence-based read-outs in high throughput and high content screening, it is clear that fluorescent molecules offer a safer, more powerful and more versatile alternative to radioligands in molecular pharmacology and drug discovery. GPCR pharmacology has benefited enormously from the application of fluorescence-based technologies and we now possess a much greater understanding of this receptor family's basic molecular mechanisms of action through the careful design and judicious use of fluorescent peptide and small-molecule-based ligands.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16125436     DOI: 10.1016/j.cbpa.2005.08.016

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  37 in total

1.  Novel fluorescent antagonist as a molecular probe in A(3) adenosine receptor binding assays using flow cytometry.

Authors:  Eszter Kozma; T Santhosh Kumar; Stephanie Federico; Khai Phan; Ramachandran Balasubramanian; Zhan-Guo Gao; Silvia Paoletta; Stefano Moro; Giampiero Spalluto; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2012-03-01       Impact factor: 5.858

2.  Novel Alexa Fluor-488 labeled antagonist of the A(2A) adenosine receptor: Application to a fluorescence polarization-based receptor binding assay.

Authors:  Miklós Kecskés; T Santhosh Kumar; Lena Yoo; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2010-05-11       Impact factor: 5.858

Review 3.  Escaping the flatlands: new approaches for studying the dynamic assembly and activation of GPCR signaling complexes.

Authors:  Thomas Huber; Thomas P Sakmar
Journal:  Trends Pharmacol Sci       Date:  2011-04-15       Impact factor: 14.819

Review 4.  The evolving small-molecule fluorescent-conjugate toolbox for Class A GPCRs.

Authors:  Andrea J Vernall; Stephen J Hill; Barrie Kellam
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 5.  Insights into GPCR pharmacology from the measurement of changes in intracellular cyclic AMP; advantages and pitfalls of differing methodologies.

Authors:  Stephen J Hill; Christine Williams; Lauren T May
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

6.  A novel fluorescent histamine H(1) receptor antagonist demonstrates the advantage of using fluorescence correlation spectroscopy to study the binding of lipophilic ligands.

Authors:  Rachel H Rose; Stephen J Briddon; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 7.  Biophysical characterization of G-protein coupled receptor-peptide ligand binding.

Authors:  David N Langelaan; Pascaline Ngweniform; Jan K Rainey
Journal:  Biochem Cell Biol       Date:  2011-04       Impact factor: 3.626

8.  Data quality in drug discovery: the role of analytical performance in ligand binding assays.

Authors:  Hermann Wätzig; Imke Oltmann-Norden; Franziska Steinicke; Hassan A Alhazmi; Markus Nachbar; Deia Abd El-Hady; Hassan M Albishri; Knut Baumann; Thomas Exner; Frank M Böckler; Sami El Deeb
Journal:  J Comput Aided Mol Des       Date:  2015-06-13       Impact factor: 3.686

9.  Dual labeled peptides as tools to study receptors: nanomolar affinity derivatives of TIPP (Tyr-Tic-Phe-Phe) containing an affinity label and biotin as probes of delta opioid receptors.

Authors:  Jane V Aldrich; Vivek Kumar; Thomas F Murray; Wei Guang; Jia Bei Wang
Journal:  Bioconjug Chem       Date:  2009-02       Impact factor: 4.774

10.  Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands.

Authors:  Jillian G Baker; Richard Middleton; Luke Adams; Lauren T May; Stephen J Briddon; Barrie Kellam; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2010-01-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.